Bacterial vaginosis (BV) during pregnancy



mollscum contagiosum :: Article Creator

Verrica Pharmaceuticals To Participate In The TD Cowen 45th Annual Health Care Conference In Boston

Verrica Pharmaceuticals Inc.

WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston.

TD Cowen 45thAnnual Health Care Conference, March 3-5, 2025Event details:Date: Monday, March 3, 2025Time: 2:30 pm ETLocation: Boston, MA

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.Verrica.Com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.Verrica.Com.

FOR MORE INFORMATION, PLEASE CONTACT:Investors:

John J Kirby Interim Chief Financial Officer jkirby@verrica.Com

Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.Com

Chris Calabrese LifeSci Advisors ccalabrese@lifesciadvisors.Com






Comments

Popular posts from this blog

Manual on meat inspection for developing countries

Rash behind ear: Causes, other symptoms, and treatment - Medical News Today

Having This One Particular Blood Type Can Help Protect You From Severe Malaria - ScienceAlert